T2 Biosystems recruits Chembio's John Sperzel as new CEO

By LabPulse.com staff writers

January 9, 2020 -- T2 Biosystems has named John Sperzel as its new president and CEO. Sperzel most recently served as president and CEO of infectious disease point-of-care diagnostics company Chembio Diagnostics.

In the statement about the appointment, T2 noted that during his tenure at Chembio, Sperzel established U.S. and international sales teams that generated significant growth, and the company also made commercial investments in Latin America and Southeast Asia. Sperzel is replacing John McDonough, who will continue to serve as nonexecutive chairman of the board.

T2 Biosystems has developed a range of tests built upon its proprietary T2 magnetic resonance (T2MR) platform, including the T2Bacteria sepsis panel, which received a new technology add-on payment (NTAP) from the U.S. Centers for Medicare and Medicaid Services (CMS) in August 2019. Soon after, in September, the company received a contract from the U.S. Biomedical Advanced Research and Development Authority that it said would accelerate development and registrational pursuits for a range of tests, including a comprehensive panel for detecting bloodborne bacterial infections.

In its own statement, Chembio announced that Sperzel had resigned and that Gail Page, who serves on the company's board of directors, has been appointed as interim CEO while Chembio searches for a permanent replacement.

Why blood cultures must come first in suspected sepsis
Patients suspected of having sepsis must get blood cultures prior to antibiotic therapy, in line with national guidelines, according to a study published...
T2 Biosystems advances new tests through BARDA funding
T2 Biosystems is accelerating the development of new direct-from-blood tests through a milestone-based funding contract with the U.S. Biomedical Advanced...
T2 Biosystems wins Medicare payment approval
T2 Biosystems said the U.S. Centers for Medicare and Medicaid Services has approved a new technology add-on payment for the firm's T2Bacteria panel sepsis...
T2Bacteria panel proves itself, but will hospitals buy in?
The T2Bacteria panel was accurate and fast for detecting five common kinds of bacteria in the blood in a multicenter study published May 13 in the Annals...
Chembio gets approval in Brazil for dengue POC test
Chembio Diagnostics has received approval from Brazilian regulatory authorities for a blood test to detect the dengue virus at the point of care (POC).

Copyright © 2020 LabPulse.com

Last Updated np 1/9/2020 4:34:21 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current